Good news for severe migraine suffers everywhere as NICE agrees to look again at Novartis’ Aimovig for migraine prevention
17th February 2020
GCP Inspections: Expectations and the dos and don’ts for hosting
19th March 2020
As we are all now terribly aware, COVID-19 is proving to be a challenge across all areas of industry.
Recently, the MHRA have announced on their blog, that they recognise the difficulties this creates for managing trials and they would like to offer some advice.
Please click HERE to read their advice in full.
